OncoSec Medical Inc (ONCSQ)

[guti]

yes, number of patients are small, but you are missing the big picture, which is the set patients are non-responders, and there was a huge difference when combined with Keytruda {50% (11/22) BORR observed at 24 weeks (42.9% [9/21] achieved RECIST v1.1 BORR).} in comparison to the monotherapy. That is for sure encouraging for Merck. But the best part is the favorable side effects,which I am guessing they are better than Keytruda's side effects without the use of electroporation